MarketCatalyst
← Back to Research
Recap

Analyst Calls: Barclays Hits NuScale, Loop Cuts Apple to Hold and BlackRock Wins a TD Cowen Upgrade

Barclays cuts NuScale to Underweight, Loop Capital downgrades Apple, and TD Cowen upgrades BlackRock to Buy in a morning of 42 analyst calls. Plus the AI-infrastructure initiations & what to watch.

Published Oct 20, 2026 · 9:39 AM ET · 5 min read

Wall Street's research desks delivered 42 rating and target changes Tuesday, Oct. 20, tilted heavily bullish: 33 Buy-equivalent calls, five Hold-equivalent and four Sell-equivalent. The headline cuts are Barclays on NuScale Power, Loop Capital on Apple and JPMorgan on EyePoint, while TD Cowen upgraded BlackRock to Buy. Initiations clustered around AI data-center infrastructure. Stocks trade normally today.

-7.4%
NuScale Power premarket at $5.27 after Barclays cut it to Underweight
+22.4%
Rapport Therapeutics premarket at $35.00; BTIG raised its target to $89
33 vs. 4
Buy-equivalent calls vs. Sell-equivalent calls in this morning's batch

Downgrades and bearish calls

Barclays downgraded NuScale to Underweight and cut its target to $5 from $11, citing commercial execution and project delays. NuScale was down 7.4% premarket at $5.27, per Benzinga. Loop Capital moved Apple to Hold from Buy and cut its target to $330 from $370 on weakening iPhone demand and an elevated valuation. JPMorgan downgraded EyePoint after failed Phase 3 results for Duravyu in wet AMD, and HSBC reiterated Reduce on CoreWeave, warning that projected 8.9% returns on invested capital fall below borrowing costs.

CompanyTickerFirmRating changePrice targetWhy
AppleAAPLLoop CapitalBuy to Hold$330 from $370Weakening iPhone demand and elevated valuation
NuScale PowerSMRBarclaysEqual Weight to Underweight$5 from $11Commercial execution and project delays
EyePointEYPTJPMorganNeutral to UnderweightNot statedFailed Phase 3 results for Duravyu in wet AMD
ZoetisZTSJefferiesBuy to Hold$83 from $103Not stated
Werner EnterprisesWERNBairdOutperform to Neutral$32 from $43Not stated
Heartland ExpressHTLDBairdOutperform to Neutral$12 from $16Not stated
RELXRELXCitiBuy to Neutral3,125p from 2,870p (London listing)Not stated
VodafoneVODBarclaysEqual Weight to UnderweightNot statedNot stated

Upgrades

TD Cowen's BlackRock upgrade carried the biggest target move in dollar terms, to $1,405 from $1,212. Two upgrades lean on AI power and infrastructure demand: BTIG on American Electric Power and Wells Fargo on Venture Global, whose target jumped to $21 from $15. Raymond James kept Akamai's $170 target but moved to Strong Buy, calling the recent AI-sector sell-off an opportunity.

CompanyTickerFirmRating changePrice targetWhy
BlackRockBLKTD CowenHold to Buy$1,405 from $1,212Accelerating earnings growth
Venture GlobalVGWells FargoEqual Weight to Overweight$21 from $15AI data center opportunities and improving leverage
American Electric PowerAEPBTIGNeutral to Buy$147Data center electricity demand
AkamaiAKAMRaymond JamesOutperform to Strong Buy$170 (unchanged)Calls the recent AI-sector sell-off an opportunity
Healthcare Realty TrustHRDeutsche BankHold to Buy$23 from $18Not stated
TrexTREXStifelHold to Buy$55Attractive valuation
ArhausARHSPiper SandlerNeutral to Overweight$13Improving sales and margin recovery
Liberty GlobalLBTYANew StreetNeutral to Buy$14Significant undervaluation despite elevated risk

New coverage

Data-center demand was the common thread. JPMorgan began nVent Electric at Overweight and Cantor Fitzgerald started Modine at Overweight, both citing data-center cooling opportunities. ADARx Pharmaceuticals drew four initiations at once, from Morgan Stanley, JPMorgan, UBS and TD Cowen.

CompanyTickerFirmRating changePrice targetWhy
nVent ElectricNVTJPMorganInitiates Overweight$167Data center and liquid-cooling opportunities
Modine ManufacturingMODCantor FitzgeraldInitiates Overweight$275Data center cooling demand
Thomson ReutersTRIJefferiesInitiates Buy$130AI products, revenue growth and operating leverage
SiTimeSITMRosenblattInitiates Buy$750Structural semiconductor growth
Restaurant Brands InternationalQSRMizuhoInitiates Outperform$85Burger King recovery and international growth
News CorpNWSARaymond JamesInitiates Outperform$35Discounted valuation
ConcentraCONStephensInitiates Overweight$45Occupational healthcare business
ArtivionAORTJefferiesInitiates Buy$31New product launches and margin expansion
FordFOxcapInitiates Overweight$15.50Not stated
ADARx PharmaceuticalsADRXMorgan Stanley, JPMorgan, UBS, TD CowenInitiations at Overweight or Buy$32 (Morgan Stanley), $38 (JPMorgan), $35 (UBS)TD Cowen initiated at Buy; target not stated
Climb BioCLYMDeutsche BankInitiates Buy$28Not stated

Reiterations and target changes

BTIG raised its Rapport Therapeutics target to $89 from $75 after positive Phase 2 results; the stock was up 22.4% premarket at $35.00, per StockAnalysis. BMO raised Alphabet to $480 from $465 and kept it a Top Pick even while projecting $325B in 2027 capital spending. Cantor Fitzgerald reiterated Overweight on SpaceX ahead of its third-quarter report after the close.

CompanyTickerFirmRatingPrice targetWhy
AlphabetGOOGLBMOOutperform, Top Pick$480 from $465Raised target despite projecting $325B in 2027 capital spending
Rapport TherapeuticsRAPPBTIGBuy$89 from $75Positive Phase 2 results
AtlassianTEAMBTIGBuy$260 from $230Not stated
AmplitudeAMPLBTIGBuy$17 from $13Not stated
Cardinal HealthCAHMizuhoOutperform$280 from $250Not stated
Gilead SciencesGILDBank of AmericaBuy$172 from $168Not stated
SeagateSTXMorgan StanleyOverweight, Top Pick reinstated$1,200 from $1,187Not stated
Advanced Micro DevicesAMDWedbushOutperform$600Reiterated
MicrosoftMSFTBMOOutperform$600Reiterated
Meta PlatformsMETARosenblattBuy$886Reiterated
NvidiaNVDAPiper SandlerOverweightNot statedNotes mixed investor sentiment and limited near-term catalysts
Western DigitalWDCMorgan StanleyOverweightNot statedFavors the stock tactically ahead of earnings
SpaceXSPCXCantor FitzgeraldOverweightNot statedExpects stronger 2027 performance and expanding handset ambitions ahead of Q3 earnings
American TowerAMTBernsteinOutperform$212 from $214Lowered target
CoreWeaveCRWVHSBCReduce$39 (unchanged)Warns projected 8.9% returns on invested capital fall below borrowing costs

What else is on the calendar

Netflix, SpaceX, United Airlines, Capital One, Chubb, Alaska Air and Intuitive Surgical report after the close today, and Meta and Tesla report Wednesday after the close. The Fed meets Oct. 27 to 28, and CME FedWatch shows roughly an 83% probability of no change, as reported by Beinsure. Housing starts and permits are also due today; no release time was sourced.

What to watch. Whether Apple and NuScale hold their premarket reactions after the open, SpaceX's report tonight against Cantor's Overweight call, and Meta on Wednesday given Rosenblatt's $886 target. Analyst calls are opinions and can be revised; this is informational, not a recommendation to buy or sell. "Not stated" means no figure or reason was given.

Readers also read

MarketCatalyst LLC is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.

Analyst Calls: Barclays Hits NuScale, Loop Cuts Apple to Hold and BlackRock Wins a TD Cowen Upgrade